Health Care [ 7/12 ] | Life Sciences Tools & Services [ 69/74 ]
NASDAQ | Common Stock
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.
It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section.
It serves various academic, government, biopharmaceutical, biotechnology, and other institutions.
The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 25 | -0.14 Increased by +66.93% | -0.11 Decreased by -27.09% |
| Oct 29, 24 | -0.30 Increased by +62.03% | -0.34 Increased by +11.76% |
| Aug 8, 24 | -0.32 Increased by +39.62% | -0.48 Increased by +33.33% |
| Apr 30, 24 | -0.50 Decreased by -13.64% | -0.50 |
| Feb 15, 24 | -0.41 Decreased by -173.33% | -0.36 Decreased by -13.89% |
| Nov 2, 23 | -0.79 Decreased by -113.51% | -0.46 Decreased by -71.74% |
| Aug 3, 23 | -0.53 Increased by +7.02% | -0.40 Decreased by -32.50% |
| May 3, 23 | -0.44 Decreased by -15.79% | -0.37 Decreased by -18.92% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 151.65 M Decreased by -1.30% | -35.75 M Increased by +61.55% | Decreased by -23.58% Increased by +61.05% |
| Jun 30, 24 | 153.10 M Increased by +4.28% | -37.90 M Increased by +39.28% | Decreased by -24.75% Increased by +41.77% |
| Mar 31, 24 | 141.01 M Increased by +5.01% | -59.95 M Decreased by -18.13% | Decreased by -42.52% Decreased by -12.50% |
| Dec 31, 23 | 183.98 M Increased by +17.76% | -48.95 M Decreased by -184.36% | Decreased by -26.61% Decreased by -141.47% |
| Sep 30, 23 | 153.64 M Increased by +17.22% | -92.99 M Decreased by -121.85% | Decreased by -60.52% Decreased by -89.26% |
| Jun 30, 23 | 146.82 M Increased by +28.10% | -62.41 M Increased by +3.17% | Decreased by -42.51% Increased by +24.41% |
| Mar 31, 23 | 134.28 M Increased by +17.28% | -50.75 M Decreased by -19.65% | Decreased by -37.79% Decreased by -2.02% |
| Dec 31, 22 | 156.23 M Increased by +8.85% | -17.21 M Increased by +6.69% | Decreased by -11.02% Increased by +14.28% |